CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Top Cited Papers
- 25 March 2011
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 331 (6024) , 1612-1616
- https://doi.org/10.1126/science.1198443
Abstract
CD40 immunotherapy shows efficacy in treating pancreatic cancer in mice and humans by eliciting antitumor immunity.Keywords
Funding Information
- National Institutes of Health (P30 CA016520, K12 CA076931)
This publication has 23 references indexed in Scilit:
- Finding the tumor copycat: Approximating a human cancerNature Medicine, 2010
- Macrophages, innate immunity and cancer: balance, tolerance, and diversityCurrent Opinion in Immunology, 2010
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic CancerScience, 2009
- The anticancer immune response: indispensable for therapeutic success?Journal of Clinical Investigation, 2008
- Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to InvasionCancer Research, 2007
- Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal AntibodyJournal of Clinical Oncology, 2007
- Prospect of Targeting the CD40 Pathway for Cancer TherapyClinical Cancer Research, 2007
- Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in miceCancer Cell, 2005
- Immunotherapy and chemotherapy — a practical partnershipNature Reviews Cancer, 2005
- Inflammation and cancerNature, 2002